Jeena Sikho Lifecare Ltd Q2 FY2026 Concall Summary

Key Takeaways

• Revenue surged 66% YoY, but guidance stays put: Both product and services segments grew 66% YoY, yet management explicitly declined to raise the FY26 revenue target of ₹650–₹700 crores, citing a seasonally weak Q3 ahead.
• Bed target achieved early, but pace now deliberately slowed: 582 beds were added in H1, hitting 2,802 total beds and exceeding the full-year target of 2,800. Management has now slowed expansion to focus on filling existing beds and lifting occupancy from 57% toward 80%.
• A strategic pivot to private insurance is underway: Government business was deliberately cut to 3% of revenue to avoid receivables risk, while private insurance revenue grew 20% QoQ. Management sees this as the next major growth driver.
• Margins are optically down on an accounting shift, not operations: EBITDA grew 129% YoY to ₹92 crores with a ~48% margin. A reported gross margin decline to 85% from 91% and a lower H1 PAT are due to Ind-AS restatement by Grant Thornton, not business deterioration.
• What to watch next quarter: Whether the franchise model launch delivers 50 new hospitals without company investment, the pace of occupancy improvement from 57%, and any clarity on the timeline for the 10 planned product launches.

Revenue Growth & Guidance

• Broad-based 66% growth: Revenue growth was driven by increasing hospital beds, filling them, improving the product delivery chain, increasing footfall in clinics and daycare, and the e-segment launch. Both product and services segments grew at the same 66% rate.
• FY26 guidance held at ₹650–₹700 crores: Despite a strong H1, management will not revise the target upward because Q3 is seasonally weak, with cold weather in November-December affecting patient volumes.
• FY27 guidance declined: When asked for a top-line estimate for FY27 that would include the new OTC business, management declined to calculate one, stating "I cannot calculate like this."
• OTC business provided a Diwali buffer: When hospital patient counts dropped during Diwali as patients took leave to go home, the OTC business provided covering support. Repeat orders have started coming, and the trend is described as very good.
• Product revenue mix question deflected: An analyst asked if the product revenue share would increase to roughly 50% of the mix. Management did not confirm any shift, saying both segments will be taken equally and the focus remains on increasing beds.

Manish Grover: "I have told you clearly that my goal is to become India's No. 1 healthcare provider company. After that, I want to become Asia's No. 1 company, then the world's No.1 naturopathy and Ayurveda company is my plan. It may take five years, eight years, ten years but we will continue."

Bed Expansion & Occupancy

• Full-year bed target exceeded in six months: 582 beds were added, taking the total to 2,802 against a March 2026 target of 2,800. Operational beds stand at roughly 2,200+, with the remaining ~600 beds ready but awaiting fire NOC, pollution NOC, and doctor hiring.
• Expansion deliberately slowed to fill beds first: Management has slowed the pace of bed additions to first fill existing beds and increase the occupancy rate, which currently stands at 57%. The revised year-end target is 3,000 beds.
• Occupancy target of 70–80% in six to eight months: The goal is to bring occupancy up from 57% to that range within the next six to eight months.
• Long-term ambition of 7,000 to 10,000 beds: This target is set for a three-to-five-year horizon.
• Revised bed target withheld: When asked for a revised target for FY26 or FY27, management declined, saying "I do not want to give a revised target" and "I have slowed the speed of the bed."

Strategic Pivot: Government to Private Insurance

• Government business deliberately cut to 3%: Management reduced exposure to avoid outstanding receivables and cash flow issues. The fixed rate of ₹8,000 per day with 25% income tax deducted leaves insufficient margin, so focus has shifted entirely to the private sector and health insurance.
• Private insurance revenue grew 20% QoQ: Management is focusing more on this segment and sees it as the next major revenue increase driver.
• Re-engagement with government depends on a new portal: The government is building a new portal with a TAT of two and a half months. Management will run a trial once it launches; if payments arrive on time, it will reconsider government business. Until then, no increase.
• Ayushman Yojana inclusion could unlock aggressive expansion: A government meeting on including Ayurveda under Ayushman Yojana has already happened, and management expects a launch "really soon." When that happens, the company plans to aggressively pick up five to ten hospitals in India.

Manish Grover: "But to earn 20% or 15% I stuck Rs. 8,000. After that, I have to pay 25% income tax in advance. So, until the system of government money is not made, I will not increase the government business."

Margins & Accounting Changes

• EBITDA grew 129% YoY to ₹92 crores: The ~48% EBITDA margin demonstrates business expansion while maintaining operational efficiency, per management.
• Gross margin decline is an accounting artifact: Gross margins fell to 85% from 91% because, under Ind-AS restatement by Grant Thornton, consumables previously booked in OPEX are now included in gross direct expense above the line, and the consumable part increased by 0.5%. Management states underlying margins are unchanged.
• H1 PAT appears lower on the same restatement: H1 PAT of ₹42–₹43 crores versus ₹47 crores last year is attributed to Ind-AS changes, including rent agreements now done for 10 years instead of 5–7 years, which increased depreciation. No reconciled figure was provided.
• 20–25% PAT margin is the healthy target: When asked about sustaining current higher margins for one to three years, management did not commit to 40% and instead described 20–25% as the healthy range, implying current margins are not expected to persist.
• Grant Thornton engagement has improved credibility: Management noted that earlier, people had doubts about whether the company was genuine; now, with Grant Thornton's stamp as the main signing firm from this quarter, it is seen as genuine.

Manish Grover: "Sir, it is because of the adoption of Indigenous. It is because of the changes that GT has made in the books, sir. Our margins are the same as before."

Partnerships & New Initiatives

• Chandan Diagnostics tie-up is a strategic bet on footfall: Chandan will set up diagnostic centers in 100% of Jeena Sikho hospitals with its own investment of ₹50 lakhs to ₹1.5 crores per center. A 30% cashback on diagnostics revenue goes to a patient card for discounts on medicines, aiming to increase patient repeat visits and trust. Chandan pays Jeena Sikho fully.
• Jeena Sikho took a 51% stake in Chandan for a minimum ₹10 crores: Management agreed to this structure because no other company was ready to give 51%. A consultant advised taking only a 51% stake rather than making small investments, and no further investment is planned.
• Franchise model launching imminently: The Jeena Sikho franchise is to be launched in two to four days, with plans to open at least 50 new hospitals under the franchise model. The company will not invest its own capital.
• Entero exclusive agreement in final stages: Entero, a listed tech-first B2B app with one lakh medical stores, will make an exclusive agreement with Jeena Sikho for Ayurveda and will not join any other Ayurveda company. Jeena Sikho will supply Ayurveda products, gaining access to one lakh medical stores on day one, with acquisition cost transferred to Entero.
• Quick commerce already live: Products are now available on Zepto, Blinkit, and all platforms, with last month's sales at ₹2.5 crores plus.
• Salesforce integration completed: The tie-up has improved lead generation, data segregation, reporting, customer feedback, and disease-specific communication. A new point-based card and referral system is being launched, with points earned from Chandan tests, medicine purchases, consultation fees, and patient referrals.

Manish Grover: "So, this is a very big strategic deal for us and I will get huge benefits from this to fill bed, sell medicines and to benefit the..."

Product Pipeline & Clinical Trials

• 10 products to be launched by end of FY26: R&D has been completed for 15–20 products, but currently only one product is in the market. The pipeline includes BP pills, diabetes pills, kidney medicines, liver medicines, and depression medicines, which management claims are unique as the first in Ayurveda with clinical trials.
• Nine clinical trials ongoing: These cover prostate cancer, breast cancer, prostate problems, migraine, and weight loss. Five or six are updated on the ICMR website.
• OTC revenue target of ₹300–₹500 crores in one to two years: When asked if FY27 is the target for this range, management deflected, saying only one product is in the market, R&D is ongoing, and more clarity will come after launching three to four more products.
• Pet Shuddhi Kit launched in four states: Distributors have been created in Delhi, Bihar, Gujarat, and Maharashtra, and sales are increasing.

Manish Grover: "Because there is no other player in Ayurveda who has undergone clinical trials and who has launched this product. So, we are first."

Geographic & International Expansion

• Domestic expansion underway across multiple cities: A Guwahati hospital has started, and management is looking for locations in Hyderabad, Chennai, Bangalore, and Bhubaneswar. A building has been finalized in Calcutta. A multi-language team covering Assamese, Bengali, Punjabi, Marathi, Tamil, Telugu, and Kannada has been assembled for patient calls.
• AI dubbing deployed for regional outreach: Management has dubbed its own voice using AI and started making videos in Assamese and Bengali. Main doctors' videos are also being dubbed.
• Nepal operations started and are profitable: Dubai/Abu Dhabi has one clinic that is 100% operational and profitable, with three more clinics being handed over and new clinic work starting.
• US project shelved: The US expansion plan was put on hold due to investor feedback to focus on India.
• Kazakhstan health center coming soon: A simple health center will be set up, with a doctor and therapist assigned.
• College tie-up progress is slow: Three tie-ups remain, the same as in Q1. Progress is delayed by government formalities such as NOCs, fire NOC, and pollution NOC. Government colleges are NGOs or trusts that cannot run profitably, so management shifted from a rent-plus-revenue-sharing model to a pure rent model. Some pipeline deals were paused to first run the existing two to three efficiently.

Guidance & Commitments

Key Metrics